Details

Autor(en) / Beteiligte

• Kowdley, Kris V
• Gordon, Stuart C
• Reddy, K. Rajender
• Rossaro, Lorenzo
• Bernstein, David E
• Lawitz, Eric
• Shiffman, Mitchell L
• Schiff, Eugene
• Ghalib, Reem
• Ryan, Michael
• Rustgi, Vinod
• Chojkier, Mario
• Herring, Robert
• Di Bisceglie, Adrian M
• Pockros, Paul J
• Subramanian, G. Mani
• An, Di
• Svarovskaia, Evguenia
• Hyland, Robert H
• Pang, Phillip S
• Symonds, William T
• McHutchison, John G
• Muir, Andrew J
• Pound, David
• Fried, Michael W

Titel

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Ist Teil von

• The New England journal of medicine, 2014-05, Vol.370 (20), p.1879-1888

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• In previously untreated patients with HCV genotype 1 infection without cirrhosis, the rate of sustained virologic response was 94% with 8 weeks of ledipasvir–sofosbuvir, 93% with 8 weeks of ledipasvir–sofosbuvir plus ribavirin, and 95% with 12 weeks of ledipasvir–sofosbuvir. More than 3 million people in the United States are chronically infected with the hepatitis C virus (HCV). 1 , 2 Although the number of new infections has been declining for decades, HCV-related morbidity and mortality are projected to continue rising for another 20 years. 3 One half to three quarters of persons currently infected with HCV have not received a diagnosis and are untreated; many will have progression to decompensated cirrhosis, hepatocellular carcinoma, and other liver complications. 3 , 4 Early diagnosis and treatment are essential to improve long-term health outcomes in this population. New guidelines from the Centers for Disease Control and Prevention . . .